Burning Rock Biotech Limited

Management did not state total revenue or EPS on the call. It did say Q1 revenue was up 4% quarter over quarter, mainly driven by the in-hospital business, and that in-hospital revenue grew year over year and sequentially. Gross margin was described as continuing to improve, but no specific gross margin figure was given. Non-GAAP gross profit minus SG&A turned positive in Q1, beating the prior goal of achieving that in the first half of 2024. Cash balance at quarter-end was RMB573 million, and full-year 2024 cash outflow guidance was RMB150 million to RMB200 million.

CEO Yusheng Han framed the quarter as evidence that the company’s multi-year push to improve profitability is working. He highlighted better sales efficiency, higher gross margin, and lower G&A and R&D spending, and said Q1’s return to profitability was “a very good sign” for Burning Rock. His tone was constructive and focused on continuing to make the business cash-flow positive over time.

CFO Leo Li emphasized operating discipline and cited a sales and marketing expense ratio of 35% of revenue, which he called a historic low. He said G&A fell significantly versus the same period last year due to headcount, office space, and other footprint reductions, and that the company ended Q1 with RMB573 million in cash. He guided to RMB150 million to RMB200 million of cash outflow in 2024, said there is a “good three-years of cash runway,” and stated the company does not need to raise capital in the near term.

There was no substantive analyst Q&A in the transcript; the call ended after management remarks. The main addressed topics were the shift from central lab to in-hospital, operating expense reductions, cash runway, and the updated cash outflow guidance. Management also noted that additional savings are expected into 2025, but said it was too early to give specific quantitative guidance for that year.